SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Gilead Lays Off Employees at California Headquarters
Follow along as BioSpace tracks job cuts and restructuring initiatives.
April 3, 2026
 · 
45 min read
 · 
BioSpace Editorial Staff
Vector illustration of a businessman unplugging polluted factory
Manufacturing
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Abstract financial chart with stock graph market.Vector illustration
Tariffs
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waive or greatly reduce the levies.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cartoon high-speed train in the white background, 3d rendering. Digital drawing.
Mergers & acquisitions
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.
April 3, 2026
 · 
3 min read
 · 
Annalee Armstrong
Business concept, vector illustrations
Weight loss
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.
April 2, 2026
 · 
3 min read
 · 
Annalee Armstrong
Control, Fluctuation, Uncertainty, Businessman balancing with an umbrella
Rare diseases
Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore regulatory clarity” for rare disease therapies. Experts on a BioSpace panel last week also acknowledged the challenges faced by a more stringent FDA.
April 2, 2026
 · 
6 min read
 · 
Heather McKenzie
EU and US crisis concept as a Broken Rope stretched with force and stressed to a decoupling metaphor for pressure on the economic and political relationship between Brussels and Washington.
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
 · 
3 min read
 · 
Annalee Armstrong
Hands protect to stop rectangle block dominos with others rectangle standing. Risk and crisis management concept.
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
April 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
April 2, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS